Germany (psilocybin policy) — Forbes published a detailed August 7 account of Germany's newly launched compassionate-use program giving treatment-resistant depression patients supervised access to psilocybin, the first such access route in the EU.
The coverage underscored the role of Filament Health's PEX010 and the initial capacity constraints at participating clinics. The high-profile reporting extended sector attention to a policy development seen as a template for broader European access.
Source: forbes.com
For the rest of that week's sector news, read our week in review.